Biosensors for the Determination of Amyloid-Beta Peptides and their Aggregates with Application to Alzheimer's Disease

DNAzyme-driven bipedal DNA walker triggered to hybridize silver nanoparticle probes for electrochemical detection of amyloid-β oligomer

Amyloid-β oligomer has been considered as a promising molecular biomarker for the diagnosis of Alzheimer's disease due to their significant neural synapse toxicity. Therefore, it is essential to create an easy approach for the selective detection of Amyloid-β oligomer that has high sensitivity and cheap cost. In this work, we developed an innovative enzyme-free electrochemical aptasensor based on the DNAzyme-driven DNA bipedal walker tactics for sensing Amyloid-β oligomer. Bipedal DNA walkers demonstrate a wider walking region, better walking kinetics, and higher amplification effectiveness than typical DNA walkers. The Mg²⁺-dependent DNAzyme drove the DNA walker, and the binding-induced DNA walker can sequentially shear MBs and form MB fragment structure. Finally, the detection probes modified AgNPs hybridized with the MB fragment structure, resulting in the multiplication of AgNPs on the electrode surface. Electrochemical stripping of AgNPs was used to test the performance of the obtained electrochemical sensor. In particular, a low detection limit of 5.94 fM and a wide linear range of 0.01 pM-0.1 nM were attained. The detection of Amyloid-β oligomer in human serum was then carried out using this bipedal DNA walker biosensor, which shown good selectivity and outstanding reproducibility, indicating its usefulness in bioanalysis.

Review: Investigating the aggregation of amyloid beta with surface plasmon resonance: Do different approaches yield different results?

Aggregation of amyloid beta into amyloid plaques in the brain is a hallmark characteristic of Alzheimer's disease. Therapeutics aimed at preventing or retarding amyloid formation often rely on detailed characterization of the underlying mechanism and kinetics of protein aggregation. Surface plasmon resonance (SPR) spectroscopy is a robust technique used to determine binding affinity and kinetics of biomolecular interactions. This approach has been used to characterize the mechanism of aggregation of amyloid beta but there are multiple pitfalls that need to be addressed when working with this and other amyloidogenic proteins. The choice of method for analyte preparation and ligand immobilization to a sensor chip can lead to different theoretical and practical implications in terms of the mathematical modelling of binding data, different mechanisms of binding and the presence of different interacting species. This review examines preparation methods for SPR characterisation of the aggregation of amyloid beta and their influence on the findings derived from such studies.

Integration of a miniature quartz crystal microbalance with a microfluidic chip for amyloid beta-Aβ42 quantitation

A miniature quartz crystal microbalance (mQCM) was integrated with a polydimethylsiloxane (PDMS) microfluidic device for on-chip determination of amyloid polypeptide–Aβ₄₂. The integration techniques included photolithography and plasma coupling. Aβ₄₂ antibody was immobilized on the mQCM surface using a cross-linker method, and the resonance frequency of mQCM shifted negatively due to antibody-antigen binding. A linear range from 0.1 µM to 3.2 µM was achieved. By using matrix elimination buffer, i.e., matrix phosphate buffer containing 500 µg/mL dextran and 0.5% Tween 20, Aβ₄₂ could be successfully detected in the presence of 75% human serum. Additionally, high temperature treatments at 150 °C provided a valid method to recover mQCM, and PDMS-mQCM microfluidic device could be reused to some extent. Since the detectable Aβ₄₂ concentration could be as low as 0.1 µM, which is close to cut-off value for Alzheimer patients, the PDMS-mQCM device could be applied in early Alzheimer’s disease diagnosis.